

Electronic witnessing in the medically assisted reproduction laboratory

Sterckx, Johan; Wouters, Koen; Mateizel, Ileana; Segers, Ingrid; De Vos, Anick; Van Landuyt, Lisbet; Van de Velde, Hilde; Tournaye, Herman; De Munck, Neelke

Published in:
Human Reproduction

DOI:
[10.1093/humrep/dead115](https://doi.org/10.1093/humrep/dead115)

Publication date:
2023

Document Version:
Accepted author manuscript

[Link to publication](#)

Citation for published version (APA):

Sterckx, J., Wouters, K., Mateizel, I., Segers, I., De Vos, A., Van Landuyt, L., Van de Velde, H., Tournaye, H., & De Munck, N. (2023). Electronic witnessing in the medically assisted reproduction laboratory: insights and considerations after 10 years of use. *Human Reproduction*, 38(8), 1529-1537.
<https://doi.org/10.1093/humrep/dead115>

Copyright

No part of this publication may be reproduced or transmitted in any form, without the prior written permission of the author(s) or other rights holders to whom publication rights have been transferred, unless permitted by a license attached to the publication (a Creative Commons license or other), or unless exceptions to copyright law apply.

Take down policy

If you believe that this document infringes your copyright or other rights, please contact openaccess@vub.be, with details of the nature of the infringement. We will investigate the claim and if justified, we will take the appropriate steps.

1 **Title:**

2 Electronic witnessing in the medically assisted reproduction laboratory: insights and considerations
3 after 10 years of use

4 **Running title:**

5 Electronic witnessing in the medically assisted reproduction laboratory

6 **Authors:**

7 Johan Sterckx¹, Koen Wouters¹, Ileana Mateizel¹, Ingrid Segers¹, Anick De Vos¹, Lisbet Van Landuyt¹,
8 Hilde Van de Velde¹, Herman Tournaye^{1,2,3}, Neelke De Munck¹

9 **Affiliation:**

10 ¹Brussels IVF, UZ Brussel, Laarbeeklaan 101, 1090 Jette

11 ²Vrije Universiteit Brussel (VUB), Department of Reproduction, Genetics and Regenerative Medicine, Biology of the Testis (BITE)
12 laboratory, Laarbeeklaan 103, 1090, Brussels, Belgium.

13

14 ³Department of Obstetrics, Gynecology, Perinatology and Reproduction, Institute of Professional Education,
15 Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Trubetskaya str. 8, b. 2,
16 119992, Moscow.

17

18

19 Abstract

20 **Study question:** What did we learn after 10 years of electronic witnessing?
21

22 **Summary answer:** When applied correctly, an electronic witnessing system can replace manual
23 witnessing in the MAR lab to prevent sample mix-up.

24 **What is known already:** Electronic witnessing systems have been implemented to improve the
25 correct identification, processing and traceability of biological materials. When non-matching
26 samples are simultaneously present in a single workstation, a mismatch event is generated to
27 prevent sample mix-up.

28 **Study design, size, duration:** This evaluation investigates the mismatch and administrator assign
29 rate over a 10-year period (March 2011 - December 2021) with the use of an electronic witnessing
30 system. Radio frequency identification tags and barcodes were used for patient and sample
31 identification. Since 2011 IVF and ICSI cycles and frozen embryo transfer cycles (FET) were included,
32 intrauterine inseminations (IUI) cycles since 2013.

33 **Participants/materials, setting, methods:** The total number of tags and witnessing points were
34 recorded. Witnessing points in the electronic witnessing system RI Witness™ represent all the
35 actions that have been performed from gamete collection through embryo production, transfer and
36 cryopreservation. Mismatches and administrator assigns were collected and stratified per procedure
37 (sperm preparation, oocyte retrieval, IVF/ICSI, cleavage stage embryo and blastocyst embryo biopsy,
38 vitrification/warming, embryo transfer, medium changeover and IUI). Critical mismatches (such as
39 mislabeling or non-matching samples within one work area) and critical administrator assigns (such
40 as non-RI Witness™-identified samples and unconfirmed witnessing points) were selected.

41 **Main results and the role of chance:** A total of 109,655 cycles were included: 53,023 IVF/ICSI,
42 36,347 FET, and 20,285 IUI cycles. The 724,096 used tags, led to a total of 849,650 witnessing points.
43 The overall mismatch rate was 0.251% (2,132/849,650) per witnessing point and 1.944% per cycle. In
44 total, 144 critical mismatches occurred over the different procedures. The yearly mean critical
45 mismatch rate was 0.017% ± 0.007% per witnessing point and 0.129% ± 0.052% per cycle. The overall
46 administrator assign rate was 0.111% (940/849,650) per witnessing point and 0.857% per cycle,
47 including 320 critical administrator assigns. Average critical yearly administrator assign rate was
48 0.039% ± 0.010% per witnessing point and 0.301 ± 0.069% per cycle.
49 Overall mismatch and administrator assign rates remained stable during the evaluated time period.
50 Sperm preparation and IVF/ICSI were most prone to critical mismatch and administrator assign.

51 **Limitations, reasons for caution:** The procedures and methods of integration of an electronic
52 witnessing system may vary from one laboratory to another and result in differences in the potential
53 risks related to sample identification. Individual embryos cannot (yet) be identified by such a system,
54 this makes extra manual witnessing indispensable at certain critical steps where potential errors are
55 not recorded. RI Witness™ still needs to be used in combination with manual labelling of both
56 bottom and lid of dishes and tubes to guarantee correct assignment in case of radio frequency
57 identification tags malfunction or incorrect use.

58 **Wider implications of the findings :** Electronic witnessing is considered to be the ultimate tool to
59 safeguard correct identification of gametes and embryos. But this is only possible when used
60 correctly and requires proper training and attention of the staff. It may also induce new risks, i.e.
61 blind witnessing of samples by the operator.

62 **Study funding/competing interest(s):** No funding was either sought or obtained for this study. JS
63 is presenting webinars on RIW for CooperSurgical.

64 **Trial registration number:** N/A

65 **Keywords:** electronic witnessing, manual witnessing, mismatch, administrator assign, error, mix-up

66 Introduction

67 Every embryologist is aware of the complexity of the workflow in a medically assisted reproduction
68 (MAR) laboratory. A multitude of procedures are being performed simultaneously at any given time at
69 different dedicated work stations. These procedures require a high level of technical expertise with no
70 room for any error, as these errors may directly impact the treatment of the patient. This creates a
71 certain level of stress in an already complex environment that may lead to human errors (*Turner et al.,*
72 *2003*). Moreover, it is a true fact that humans inevitably are prone to making errors (*Myhre et al.,*
73 *2000*). During MAR, the crucial steps susceptible to human error are patient identification and the
74 traceability of gametes and embryos (*Kennedy et al., 2007*).

75 In any laboratory where a quality management system is installed, non-conformances, i.e. failure to
76 conform to the standard requirement or protocol during treatment, should be registered. Monitoring
77 the occurrence, grade of severity and impact of these non-conformances on patient outcome allows
78 for measures and appropriate procedures to be installed to prevent their re-occurrence (*Sakkas et al.,*
79 *2018*). A mix-up of gametes and/or embryos has the highest grade of severity. It is therefore the
80 responsibility of any MAR laboratory to avoid this event at any time (*Mark et al., 2020*).

81 As recommended by international guidelines and directives (*Commission Directive, 2006; ESHRE*
82 *Guideline Group on Good Practise in IVF labs, 2016; Human Fertilisation and Embryology Authority,*
83 *2021; EDQM Tissues and cells, 2022*), specific protocols concerning correct identification, processing
84 and traceability of biological materials must be in place. The combination of clearly and permanently
85 labelled devices containing biological material, the separate processing of biological materials from
86 different patients in time and space, and the witnessing of critical steps are some of the key elements
87 to avoid mix-up errors.

88 For a very long time, witnessing via a double-checking approach was the only possible solution. This
89 involves a verbal double check and extra pair of eyes of a second operator before the executing
90 colleague can start or continue with a specific procedure. A handwritten signature of the witness is
91 required to guarantee the traceability of this check. This approach, however, has some limitations: (i)
92 it can become rather tedious to be applied in a complex and busy environment as it takes two persons
93 to perform the witnessing, (ii) independent redundancy, (iii) unintentional blindness and (iv)
94 ambiguous accountability (*De los Santos et al., 2013*). The need to interrupt a second operator and the
95 automaticity in the constant repetitive task of manual witnessing, is a recipe for making double
96 witnessing prone to human errors (*Toft et al., 2005, 2009*) and difficult to perform for each procedure
97 (*Rienzi et al., 2017*). To tackle these issues, electronic witnessing systems (EWS) have been developed
98 and introduced in MAR laboratories.

99 EWS systems are mainly based on radio-frequency identification (RFID) and/or barcode labelling of all
100 tubes and dishes. With barcode labelling, the operator needs to scan all barcodes manually, whereas
101 systems with RFID automatically detect all RFID labelled consumables by a reader integrated in the
102 workstation. Thanks to this automation, procedural electronic witnessing steps are less likely to be
103 circumvented by the operator (*De los Santos et al., 2013*). RFID readers integrated into the workstation
104 have the additional advantage that the biological material of only one patient can be present in a given
105 workstation, which will help to ensure that a mismatch is prevented. In addition, EWS have the
106 advantage over double witnessing in improving risk reduction and decreasing time needed to witness
107 (*Rienzi et al., 2015, Holmes et al., 2021*). Since the introduction of EWS systems, error rates are being
108 presented as mismatch rates. However, administrator assigns, i.e. when the administrator needs to
109 assign a previously untagged or incorrectly assigned tag, have not previously been presented as an
110 error rate when using EWS.

111 The aim of the current study was to evaluate our EWS after 10 years of use and to analyse how this
112 system impacted our mismatch rates and admin assigns over time.

113 **Materials and Methods**

114 *Study design*

115 This is a single centre retrospective analysis of all conventional IVF/ICSI, intrauterine inseminations
116 (IUI) and frozen embryo transfer (FET) cycles performed with the use of EWS RI Witness™
117 (CooperSurgical), between March 2011 and December 2021. Cycles with IVF/ICSI and FET were
118 included since the start in 2011, while IUI cycles were only included since 2013. Implementation of the
119 barcode labels for labelling of cryopreserved samples started in 2014. For this study, no approval from
120 the Local Ethical Committee was required.

121 *MAR procedures subject to witnessing*

122 The following eight procedures were followed over time: (i) sperm preparation including sperm
123 preparation for IVF/ICSI/IUI and cryopreservation, (ii) oocyte retrieval (OR), (iii) IVF/ICSI including
124 denudation of oocytes before ICSI or cryopreservation and after IVF insemination, (iv) cleavage stage
125 embryo and blastocyst biopsy excluding the tubing of the biopsied samples, (v) embryo transfer, (vi)
126 medium changeover (vii) cryopreservation of oocytes and embryos and (viii) IUI. The number of
127 witnessing points were collected and stratified per procedure.

128 *Electronic witnessing system*

129 RI Witness™ (RIW) is an electronic witnessing system based on RFID cards and RFID tags which are
130 automatically detected by an RFID reader once they are in the detectable range (Supplementary Figure
131 S1 A+B). RIW uses printed labels with barcodes to identify cryopreserved gametes and embryos. As
132 these are not automatically detected by the reader, the operator needs to scan them manually. Every
133 sample needs to be labelled with an RFID tag (on the bottom of dishes or the side of tubes) or barcode
134 and assigned by the operator into the EWS through a witnessing point (WP). Based on the lab
135 procedures, the lab representatives have to set up an EWS-WP diagram. Whenever new laboratory
136 procedures are introduced, new WPs and items can be added in the EWS-WP diagram. Every step in a
137 lab procedure, where it is necessary to have a witnessing step, is hereby defined as a WP. By selecting
138 a WP, not only the identity of that specific patient will be transmitted to the RFID tag, the tag will also
139 be marked as a specific item (e.g. sperm pot, ICSI dish). The date, hour, working station and operator
140 who marked the item will be recorded as well. Only when a specific combination of items is presented
141 in the working area, the system will pop-up the possible WP (Supplementary Figure S1 C). By selecting
142 the corresponding WP, the action will be recorded in the EWS. A WP can also be used to confirm a
143 specified action without the necessity of a new RFID tag. The number of WP may vary from one
144 procedure to another: OR, biopsy, embryo transfer, medium changeover, cryopreservation of oocytes
145 and embryos and IUI only require one or two WPs. Sperm preparation and IVF/ICSI are a consecutive
146 sequence of multiple WP (Supplementary Figure S2).

147 In our setting, the EWS is used in combination with the manual writing of patient's name and a unique
148 patient cycle identifier on lid and bottom of all dishes and on tubes. In our current setting, labelling is
149 only performed at the time a dish or tube will be used. To keep this logistically as simple as possible
150 and while moving to a completely paperless lab, it was deliberately chosen not to use the pre-printed
151 labels provided by the EWS. A double manual check remains in place for all entry points in the EWS
152 (for instance receiving a sperm sample), when assigning donor samples to an acceptor, when embryo
153 or cryopreserved straw numbers need to be verified and when the lab file is assigned. The paper lab

154 file is RFID labelled and is required to confirm a WP when starting sperm preparation, denudation of
155 oocytes and for IVF insemination. An RFID patient card is created, with mandatory double check, and
156 will be used to confirm the patient's identity at the start of oocyte retrieval, surgical retrieval of sperm
157 and embryo transfer.

158 Each operator has a unique login into the system. Only the basic elements of using the EWS are part
159 of the introduction training. Once the operator is trained for a specific procedure (for instance sperm
160 preparation or OR), the relevant parts of the RIW system are explained. As operators are trained for
161 all procedures, they will gradually know the complete RIW flow.

162 *Mismatch*

163 A mismatch (MM) event is referring to a situation where two or more non-matching samples are
164 simultaneously present in a single workstation on a RFID reader. A visual and audible signal will appear
165 to stop the operator's actions. A real mismatch error, e.g. a mix-up of two non-matching gamete or
166 embryo sources, will hereby be prevented. Even when there is no intention to do any manipulation
167 (false mismatch), a mismatch event may also occur once multiple samples of different non-matching
168 individuals are on or too close to an RFID reader. Continuing the impeded process is only possible by
169 entering an explanation on what went wrong, this information can be used to distinguish true from
170 false mismatches. True mismatches were selected and defined as critical (i) when non-matching
171 samples were present within one working area prior to the manipulation and (ii) when mislabeling
172 during cryopreservation procedures occurred: in this case straws are prepared for a patient that do
173 not correspond to the patient's identity. Critical MM (CMM) were collected and stratified for the
174 above-described eight procedures. MM are expressed as total numbers, percentages (%) and average
175 \pm standard deviation.

176 *Administrator assign*

177 An administrator assign (AA) is used when a tube or dish is labelled via an incorrect WP, when the tag
178 was not assigned, when no tag was present or when a previously assigned tag cannot be read anymore.
179 Only a specific group of administrators is able to perform AA after thorough checking of previous steps
180 of the process. In the EWS-WP diagram, all WP are outlined for the different procedures by drawing
181 different combinations that can be selected when different items are present in the reader. In this way,
182 when an operator wants to assign a new RFID tag, only the most possible applicable WP will be
183 presented to the operator. Although the operator is shown only this selection of WP, it may happen
184 that the allocation was not done properly by choosing an incorrect WP. In this case the patient's
185 identity will be transferred correctly, but a wrong item's name will be given to that specific tag. This in
186 turn will cause that a next WP cannot be performed and an administrative correction will be required.
187 Much more dangerous is that an operator has forgotten to make the EWS assignment or has forgotten
188 to label the sample at all. In those cases, an electronic or manual witness is missing. These AA were
189 selected and defined as critical. Critical AA (CAA) were collected and stratified for the eight above-
190 mentioned procedures. AA are expressed as total numbers, percentages (%) and average \pm standard
191 deviation.

192 *Statistical analysis*

193 Every MAR laboratory should decide whether the increase or decrease of a single (C)MM or (C)AA may
194 have a significant impact on traceability or not. This is a descriptive study, no statistical analysis was
195 performed.

196 **Results**

197 During this study period 53,023 oocyte retrievals (OR), 36,347 FET cycles and 20,285 IUIs were
198 performed with the use of EWS. To cover this total of 109,655 cycles, a total of 724,096 RFID tags and
199 58,720 barcodes were used resulting in 849,650 registered WP (Table I). An overall average of $7.701 \pm$
200 0.443 WP per cycle was obtained.

201 Total number of WP per procedure were: (i) sperm preparation: 255,134, (ii) oocyte retrieval: 69,585,
202 (iii) IVF/ICSI: 195,949, (iv) cleavage stage embryo and blastocyst biopsy: 17,978, (v) embryo transfer:
203 65,650, (vi) medium changeover: 30,669, (vii) cryopreservation of oocytes and embryos: 75,556 and
204 (viii) IUI: 40,513. Sperm preparation and IVF/ICSI involve a sequence of multiple steps that are
205 controlled through the EWS, these therefore include the largest proportion of WP (Figure 1).

206 **Mismatch**

207 The overall MM rate was 0.251% (2,132/849,650) per WP and 1.944% (2132/109,655) per cycle with
208 an average of $0.268\% \pm 0.078$ and $2.047\% \pm 0.597$ per year, respectively. When selecting only CMM, the
209 rate was 0.017% (144/849,650) per WP and 0.131% (144/109,655) per cycle with an average rate of
210 $0.017\% \pm 0.007$ and $0.129\% \pm 0.052$ per year, respectively. With an average of only 13.1 CMM/year, a
211 reduction or increase of 1 CMM/year can influence this average. The overall MM rate per WP
212 decreased slowly over time, the CMM per WP remained stable (Figure 2A). However, within the MM,
213 the proportion of CMM increased over time (Figure 2C).

214 Out of the 2,132 MM, 144 CMM occurred in the eight different procedures: (i) sperm preparation: 61,
215 (ii) oocyte retrieval: 3, (iii) IVF/ICSI: 37, (iv) cleavage stage embryo and blastocyst biopsy: 1, (v) embryo
216 transfer: 11, (vi) medium changeover: 3, (vii) cryopreservation of oocytes and embryos: 25, and (viii)
217 IUI: 3 (Table II). The proportion of CMM per procedure on the total number of CMM is outlined in
218 Figure 3. Procedures with the highest CMM rate were sperm preparation, with a steep increase since
219 2014, and IVF/ICSI with a steep decline in CMM since 2015. All other procedures remained stable with
220 a very low incidence over time. Most common errors observed in both procedures were: starting the
221 sperm processing with a wrong sample; wrong labelling at cryopreservation of sperm and having a
222 non-matching sperm sample and oocytes together when preparing an ICSI insemination dish. The non-
223 critical MM mainly occurred in the administrative preparation of the RFID cards and paper lab files, the
224 manipulation of donor and the assigned acceptor samples and when taking samples intended for
225 training.

226 **Administrator assign**

227 The overall AA rate was 0.111% (940/849,650) per WP and 0.857% (940/109,655) per cycle with an
228 average of $0.113\% \pm 0.027$ and $0.866\% \pm 0.212$ per year, respectively. When selecting only CAA, the
229 rate was 0.037% (320/849,650) per WP and 0.292% (320/109,655) per cycle with an average rate of
230 $0.039\% \pm 0.010$ and $0.301\% \pm 0.069$ per year, respectively. The AA rate and CAA rate per WP remained
231 stable over the years (Figure 2B), however, the proportion of CAA/AA is much higher compared to the
232 CMM/MM (Figure 2C).

233 Occurrence of the CAA per procedure was: (i) sperm preparation: 83, (ii) oocyte retrieval: 34, (iii)
234 IVF/ICSI: 173, (iv) cleavage stage embryo and blastocyst biopsy: 3, (v) embryo transfer: 0, (vi) medium
235 changeover: 21, (vii) cryopreservation of oocytes and embryos: 6, (viii) IUI: 0 (Table II). The proportion
236 of CAA per procedure on the total number of CAA is outlined in Figure 3.

237 Re-emerging procedures with high levels of CAA were sperm preparation with an increase in CAA since
238 2019 and IVF/ICSI which remained stable, but high over time. Most common observed errors in both
239 procedures were the failure to assign the final sperm tube during sperm processing (Supplementary

240 Figure S2: WP Sperm wash) and not assigning the culture dish before culturing the injected oocytes
241 (Supplementary Figure S2: WP Post ICSI). Both are the final WP of a procedure, before the samples are
242 released from the working station.

243 The AA rate due to network system failure was 2.2% (21/940). Such system failure only occurred in
244 one weekend in 2015, where laboratory staff resorted to witnessing by a second operator for all lab
245 processes. RFID tag failure occurred in 14.7% (138/940) of all the AA. RFID tags were assigned correctly
246 but were found to be no longer working in a next step. Correct identification of samples was possible
247 due to double labelling of tubes and dishes.

248 Discussion

249 This is the first study reporting on a long-time experience with electronic witnessing in a busy lab in a
250 single centre with high level of activity. With close to one million of WP analysed during the study
251 period, only 0.251% lead to a MM and 0.111% to an AA. When only considering critical actions, where
252 a potential mix-up is prevented, only 0.017% CMM and 0.037% CAA were recorded. Sperm preparation
253 and IVF/ICSI were most prone to (C)MM and (C)AA.

254 The potentially prevented true mismatch rate in this study, presented as CMM rate (0.017%) is lower
255 than previously published data which are based on a small number of WP (803 to 17,435) evaluated
256 during a short period: 0.12%, 0.05%, 0.46% and 0.05% (*Brunetti et al. 2012, Rienzi et al. 2015, Gupta*
257 *et al. 2020, Holmes et al. 2021*). This discrepancy may be explained by a different interpretation and
258 classification of critical or true mismatches between publications.

259 Highest (C)MM rates were observed during sperm preparation and IVF/ICSI, as these procedures have
260 a more extensive WP diagram. An average sperm preparation or ICSI procedure takes a longer
261 processing time and contain a sequence of three WP, while OR and biopsy contain one and two WP,
262 respectively. This makes these procedures more prone to MM in general. The semen samples are also
263 brought in and out of the working area several times for centrifugation, hence increasing the risk of
264 potential errors during sperm preparation. For IVF/ICSI, gametes of matching maternal and paternal
265 origin are brought together for insemination, a procedure that requires utmost attention.

266 Unlike the other procedures where CMM dropped or remained low over time, a significant increase
267 occurred only during the sperm preparation procedures (Figure 3 (i)). Incorrect verification of identity
268 on sperm pots, tubes and barcodes are the main cause of this increase. A certain laxity to properly
269 read labels may occur, as operators believe the EWS will catch potential errors. The gradual increase
270 in workload has probably reached a threshold in 2015 for many operators above which they are more
271 prone to errors. In an initial stage, the workflow for sperm sample preparation was revised to allow an
272 improved spreading of samples. In a second phase, alternative sperm preparation techniques are being
273 explored that are less labor intensive. Sperm preparation, together with warming of gametes and
274 embryos, have also previously been reported to be the procedures with the highest risk of MM (*Rienzi*
275 *et al. 2015, Holmes et al. 2021*).

276 It is noteworthy that only 6.75% (144/2,132, corresponding to one CMM every four months) of the
277 total mismatch events were considered critical.

278 The EWS will prevent any mix-up error, but prevention can only be assured when the operator is using
279 it correctly. The standard operating procedure is to move gametes and embryos from one recipient to
280 another on the reader only and to confirm every WP before any manipulation to assure that the EWS
281 can prevent a potential error. If the operator forgets to select a WP, the action will not be registered,
282 despite the audible signal that is generated when removing an unassigned tag from the reader, hence

283 a CAA is generated and a correction by an administrator is required. An AA is only allowed after
284 thorough verification: patient's history in the EWS, other simultaneously conducted procedures,
285 strictly separating the cycles that have already been processed from the ones to be processed. Inability
286 to trace back the history of a sample forces the operator to ask for a second sperm sample, to discard
287 oocytes or to perform a genetic test on embryos to confirm their parental origin. It is clear that the
288 number of CAA should be reduced to the absolute minimum.

289 Although, working with an EWS seems to be very intuitive, workload for the operator may influence
290 the correct use of it. An increase of CAA can be noticed during medium changeover (figure 3 (vi)).
291 Together with data-input, medium changeover was a task for the operator performing the ORs until
292 2018. Redistribution of this task, has led to a decrease in CAA since 2019 (figure 3 (vi)). This in contrast
293 with sperm preparation, where workload increased over time whilst task allocation and number of
294 working stations remained stable. This may explain that just as with CMM, sperm preparation also
295 scored highest for CAA. After sperm preparation, the final sperm tube is moved from the andrology to
296 the embryology laboratory. It occurred that at start of the IVF/ICSI the sperm tube was found not to
297 be correctly RFID labelled. Operators where then returning to the andrology lab to assign the tube,
298 while the correct procedure here would have been an AA to maintain full traceability. The awareness
299 of applying the correct registration in 2019 (AA instead of assigning) explains the low occurrence of
300 CAA in the period 2014-2018 followed by a steep increase in CAA from 2019 onwards (Figure 3 (i)).

301 An RFID tag is not an error-free substitute for the classic handwritten or printed labelling of samples
302 with names and/or unique cycle identifiers. Hardware and software, requiring a highly reliable
303 network, are always needed to read the RFID tag, but there is also a risk of its malfunctioning. It
304 remains unclear why a RFID tag initially works but can become undetectable in time. These AA can only
305 be resolved if the tagging is combined with manual labelling of names and unique cycle numbers. As
306 lids of dishes can easily be transferred from one dish to the other, manual labelling on the bottom or
307 side of dishes is a minimal requirement.

308 Implementing an EWS is a way to standardize all sample identification witnessing procedures. It
309 eliminates, with some exceptions, the need for the second human witness, it allows operators to start
310 and complete a procedure independently with full traceability of all (crucial) steps. Even when
311 performing IUI, the use of an EWS can assure the use of the correct gametes without the need for a
312 second witness. This helps in gaining efficiency in staff deployment which is important at any level
313 when managing a fertility clinic. By using an EWS, not only interruptions of operators performing
314 delicate procedures are reduced, it may also save time (*Holmes et al. 2021*). Replacing the manual
315 double witnessing by an EWS is part of the automation that is already ongoing in the modern MAR lab
316 (*Bori et al., 2021*). As full traceability (operator, time, steps, working station) is now automatically
317 recorded, EWS also reduce the administrative registration of double-witnessing steps.

318 When starting a procedure in the lab, it is important for each embryologist to be confident that all
319 previous steps were performed correctly. When proper entry and exit points are generated for all
320 samples it is, according to our experience, safe to solely rely on the EWS upon gamete insemination,
321 which is in contrast to the double manual witnessing recommendation by HFEA (*Human Fertilisation
322 and Embryology Authority, 2021*). In our perception, the use of EWS increases the trust not only within
323 the lab, but also from the patient's point of view as already confirmed by previous publications (*Forte
324 et al., 2016; Holmes et al., 2021*).

325 The integrated RFID reader into the workstation obliges the operator to work with only one patient at
326 a time. This implies that manipulation of non-matching samples is excluded for procedures where
327 gametes and embryos stay within one working area with a strict control of entry. In our experience,

328 sperm preparation procedures, where the RFID reader is only occupying 10% of the working area
329 (Supplementary Figure S1C), is the most sensitive procedure in the EWS. Workload (necessity of
330 multiple sperm samples to be processed in limited time span), involuntary automaticity and multiple
331 WP combined with multiple centrifugation steps outside the reader may lead to the blind/wrong
332 witnessing. An EWS-cage comprising the complete working area and centrifuge would reduce the
333 number of errors in sperm preparation tremendously.

334 It can be questioned if such an EWS-cage has any toxic effect on embryo development. These safety
335 questions were already raised since the introduction of RFID based EWS. The RFID tag, which is tested
336 for toxicity per batch, is a passive item and is not expressing radio waves. The readers in the lab are
337 using only low level (13.56 MHZ) frequencies emitted in a short range unlike the ubiquitous presence
338 of the high levels used for WIFI and other mobile technologies. It is difficult to prove whether or not
339 EWS may have any impact on embryo development, considering the overall presence of radio
340 technology out of our control. Gupta and colleagues (2020) evaluated 128 cycles with and 59 IVF cycles
341 without exposure to the RFID readers and found the EWS was not adversely affecting gametes and
342 embryos.

343 One of the most dangerous disadvantages of the EWS is the unavoidable involuntary laxity of
344 operators. Operators rely 100% on the system and they read names with a 'single' eye, as EWS will
345 read it anyway. Even though patient information is displayed on the tablets attached to the EWS, they
346 are often positioned outside the laminar flows, in an ergonomically bad position for reading.
347 Integrating this system in the working area is thus beneficial when not interfering with the workspace.
348 An intensive training, increasing awareness and indicating consequences concerning laxity of all
349 operators is the start of any good laboratory practice. Reporting on performance indicators related to
350 identification and traceability per operator including CMM/CAA will help to improve the EWS flow of
351 each laboratory and will also alert operators when repetitive errors are being reported (*Fabozzi et al.,*
352 *2020*). In the current setting, most MM and AA were sporadic events by different operators: good
353 communication of the type and consequence of MM and AA and follow-up of possible recurring events
354 were implemented here.

355 Identifying individual embryos in an EWS is not (yet) available. This makes double manual witnessing
356 indispensable at certain critical steps, for instance when moving embryos for biopsy and vitrification,
357 as potential 'numbering' errors cannot be recognized by RFID witnessing. A tracking system, where the
358 operator needs to indicate which embryo is moved, within RIW is recently introduced and needs
359 further validation to assure its safety as a replacement for the manual witnessing at those steps.

360 To conclude, EWS is a good addition to the manual witnessing for sample identification, but only when
361 applied in a correct way. Our results indicate that potential errors may still occur even though the EWS
362 is already in use for a long period of time. Real mix-up of samples is prevented by the EWS, although it
363 can never be proven whether or not these errors would have been intercepted by a manual check too.
364 At least, prevented mix-ups are now recorded, which was very time-consuming to quantify with
365 manual witnessing. Any intervention by an operator in any EWS remains a possible source for errors,
366 and these should be reduced to an absolute minimum. Therefore, an EWS should always be used in
367 combination with the manual/printed labelling of bottom and top of dishes and tubes to guarantee
368 correct assignment in case of RFID/network failure or administrator assign. Like this, not only the best
369 embryo will be transferred, but also the correct one.

370

371 **Data availability statement**

372 The data underlying this article will be shared on reasonable request to the corresponding author.

373 **Authors' roles**

374 J.S.: conception and design, acquisition of data, analysis and interpretation of data, writing the article
375 and critical review and acceptance of the article. K.W., I.M., I.S., A.D.V., L.V.L and H.T.: critical review
376 and acceptance of the article. N.D.M.: conception, design and critical review and acceptance of the
377 article.

378 **Funding**

379 No funding was either sought or obtained for this study.

380 **Conflict of interest**

381 J.S. is presenting webinars on RIW for CooperSurgical.

382 **Figure legends**

383 Figure 1: Proportion of witnessing points per procedure

384 Figure 2: A: Yearly overview of percentage of mismatches per witnessing point and critical mismatches per
385 witnessing point B: Yearly overview of percentage of administrator assigns per witnessing point and critical
386 administrator assigns per witnessing point; C: Proportion of percentages of critical mismatches per total
387 mismatches and percentage of critical administrator assigns per total administrator assigns; WP: witnessing
388 point; MM: mismatches; CMM: critical mismatches; AA: administrator assign; CAA: critical administrator assign
389

390 Figure 3: Proportion of critical mismatches per procedure on the total of critical mismatches and
391 proportion of critical administrator assigns per procedure on the total of critical administrator
392 assigns; CMM: critical mismatches; CAA: critical administrator assign

393 Supplementary Figure S1: A: Integrated RFID reader with the detectable range marked within the red
394 lines; B: RFID sperm reader with the detectable range marked within the red square; C: View of the
395 possible next witnessing points when a sperm sample and an empty, unassigned tube is on the
396 reader; RFID: radio-frequency identification

397 Supplementary Figure S2: witnessing points overview of procedures sperm preparation and oocyte
398 retrieval to ICSI; RFID: radio-frequency identification

399 **References**

400 Bori L, Meseguer M. Will the introduction of automated ART laboratory systems render the majority
401 of embryologists redundant? *Reprod Biomed Online*. 2021 Dec;43(6):979-981. doi:
402 10.1016/j.rbmo.2021.10.002. Epub 2021 Oct 12. PMID: 34753681.

403 Brunetti, Xavier & Bird, Sophie & Rogers, Shaun & Thornhill, Alan. (2012). OP-2 Identifying human error
404 in the IVF laboratory using electronic witnessing. *Reproductive BioMedicine Online*. 24. S1.
405 10.1016/S1472-6483(12)60126-6.

406 Commission directive 2006/86/EC of 24 October 2006 implementing Directive 2004/23/EC of the
407 European parliament and of the Council as regards traceability requirements, notification of serious
408 adverse reactions and events and certain technical requirements for the coding, processing,
409 preservation, storage and distribution of human tissues and cells. *Off J Eur Union* 2004;L294:32

410

411 De los Santos MJ, Ruiz A. Protocols for tracking and witnessing samples and patients in assisted
412 reproductive technology. *Fertil Steril*. 2013 Dec;100(6):1499-502. doi:
413 10.1016/j.fertnstert.2013.09.029. PMID: 24427790.
414
415 EDQM Guide to the quality and safety of tissues and cells for human application, European
416 Directorate for the Quality of Medicines & HealthCare of the Council of Europe, 2022 5th edition
417
418 ESHRE Guideline Group on Good Practice in IVF Labs, De los Santos MJ, Apter S, Coticchio G, Debrock
419 S, Lundin K, Plancha CE, Prados F, Rienzi L, Verheyen G, Woodward B, Vermeulen N. Revised
420 guidelines for good practice in IVF laboratories (2015). *Hum Reprod*. 2016 Apr;31(4):685-6. doi:
421 10.1093/humrep/dew016. Epub 2016 Feb 17. PMID: 26908842.
422
423 Fabozzi G, Cimadomo D, Maggiulli R, Vaiarelli A, Ubaldi FM, Rienzi L. Which key performance
424 indicators are most effective in evaluating and managing an in vitro fertilization laboratory? *Fertil*
425 *Steril*. 2020 Jul;114(1):9-15. doi: 10.1016/j.fertnstert.2020.04.054. Epub 2020 Jun 9. PMID: 32532495.
426
427 Forte M, Faustini F, Maggiulli R, Scarica C, Romano S, Ottolini C, Farcomeni A, Palagiano A, Capalbo A,
428 Ubaldi FM, Rienzi L. Electronic witness system in IVF-patients perspective. *J Assist Reprod Genet*.
429 2016 Sep;33(9):1215-22. doi: 10.1007/s10815-016-0759-4. Epub 2016 Jul 7. PMID: 27387889; PMCID:
430 PMC5010816.
431
432 Gupta S, Fauzdar A, Singh VJ, Srivastava A, Sharma K, Singh S. A Preliminary Experience of Integration
433 of an Electronic Witness System, its Validation, Efficacy on Lab Performance, and Staff Satisfaction
434 Assessment in a Busy Indian *in vitro* Fertilization Laboratory. *J Hum Reprod Sci*. 2020 Oct-
435 Dec;13(4):333-339. doi: 10.4103/jhrs.JHRS_66_20. Epub 2020 Dec 28. PMID: 33627984; PMCID:
436 PMC7879839.
437
438 Kennedy C.R., D. Mortimer, Risk management in IVF, *Best Practice & Research Clinical Obstetrics &*
439 *Gynaecology*, Volume 21, Issue 4, 2007, Pages 691-712, ISSN 1521-6934,
440 <https://doi.org/10.1016/j.bpobgyn.2007.02.009>
441
442 Human Fertilisation and Embryology Authority. Code of Practice 9.0, 2021
443
444 Holmes R, Wirka KA, Catherino AB, Hayward B, Swain JE. Comparison of electronic versus manual
445 witnessing of procedures within the in vitro fertilization laboratory: impact on timing and efficiency. *F*
446 *S Rep*. 2021 Apr 28;2(2):181-188. doi: 10.1016/j.xfre.2021.04.006. PMID: 34278352; PMCID:
447 PMC8267391.
448
449 Mark P. Trollice, M.D., Jody Lyneé Madeira, JD, Ph.D., and Steven R. Lindheim, M.D., M.M.M. IVF
450 errors: Is this only the tip of the iceberg? *Fertility and Sterility* 2020 Jan 25.
451
452 Myhre BA, McRuer D. Human error-a significant cause of transfusion mortality. *Transfusion*. 2000
453 Jul;40(7):879-85. doi: 10.1046/j.1537-2995.2000.40070879.x. PMID: 10924620.
454
455 Rienzi L, Bariani F, Dalla Zorza M, Romano S, Scarica C, Maggiulli R, Nanni Costa A, Ubaldi FM. Failure
456 mode and effects analysis of witnessing protocols for ensuring traceability during IVF. *Reprod Biomed*
457 *Online*. 2015 Oct;31(4):516-22. doi: 10.1016/j.rbmo.2015.06.018. Epub 2015 Jul 7. PMID: 26292780.
458
459 Rienzi L, Bariani F, Dalla Zorza M, Albani E, Benini F, Chamayou S, Minasi MG, Parmegiani L, Restelli L,
460 Vizziello G, Costa AN; Italian Society of Embryology, Reproduction and Research (SIERR), Italy.

461 Comprehensive protocol of traceability during IVF: the result of a multicentre failure mode and effect
462 analysis. *Hum Reprod.* 2017 Aug 1;32(8):1612-1620. doi: 10.1093/humrep/dex144. PMID: 28575413.
463
464 Sakkas D, Barrett CB, Alper MM. Types and frequency of non-conformances in an IVF laboratory.
465 *Hum Reprod.* 2018 Dec 1;33(12):2196-2204. doi: 10.1093/humrep/dey320. PMID: 30388228.
466
467 Toft B, Gooderham P. Involuntary automaticity: a potential legal defence against an allegation of
468 clinical negligence? *Qual Saf Health Care.* 2009 Feb;18(1):69-73. doi: 10.1136/qshc.2007.024273.
469 PMID: 19204136.
470
471 Toft B, Mascie-Taylor H. Involuntary automaticity: a work-system induced risk to safe health care.
472 *Health Serv Manage Res.* 2005 Nov;18(4):211-6. doi: 10.1258/095148405774518615. PMID:
473 16259668.
474
475 Turner CL, Casbard AC, Murphy MF. Barcode technology: its role in increasing the safety of blood
476 transfusion. *Transfusion.* 2003 Sep;43(9):1200-9. doi: 10.1046/j.1537-2995.2003.00428.x. PMID:
477 12919421.

Figure 1: Proportion of witnessing points per procedure




Figure 2: Mismatches and administrator assigns over the years of using the electronic witnessing system. A: Yearly overview of the percentage of mismatches (blue) and critical mismatches (orange) per witnessing point B: Yearly overview of percentage of administrator assigns (blue) and critical administrator assigns (orange) per witnessing point; C: Proportion of critical mismatches per total mismatches (blue) and proportion of critical administrator assigns per total administrator assigns (orange). WP: witnessing point; MM: mismatches; CMM: critical mismatches; AA: administrator assign; CAA: critical administrator assign.








Figure 3: Proportion of critical mismatches per procedure on the total of critical mismatches and proportion of critical administrator assigns per procedure on the total of critical administrator assigns; CMM: critical mismatches; CAA: critical administrator assign


(i) sperm preparation




(v) embryo transfer




(ii) oocyte retrieval




(vi) medium changeover




(iii) IVF/ICSI




(vii) cryopreservation of oocytes and embryos





(iv) cleavage stage and blastocyst biopsy




(viii) IUI



Supplementary Figure 1: A: Integrated RFID reader with the detectable range marked within the red lines; B: RFID sperm reader with the detectable range marked within the red square; C: View of the possible next witnessing points within the red lines when a sperm sample and an empty, unassigned tube is on the reader; RFID: radio-frequency identification



Supplementary Figure S2: witnessing points overview of procedures sperm preparation and oocyte retrieval to ICSI; RFID: radio-frequency identification



+ patient lab file

a paper lab file with RFID label is prepared on day -1 with double manual check

+ patient RFID card

a RFID card is prepared on day -1 with double manual check

+ RFID tag

a RFID tag is placed on the recipient



referring to the corresponding witnessing point

Table I: Overview of the total number of cycles, witnessing points, tags and barcodes used per year

Year	N of OR	N of FET	N of IUI	Total N of cycles	N of WP	N of RFID tags	N of barcodes	Average WP/cycle
2011	3,829	2,040		5,869	41,695	36,130		7.104
2012	4,378	2,317		6,695	47,815	42,639		7.142
2013	4,635	2,267	1,029	7,931	65,105	61,577		8.209
2014	4,445	2,374	2,743	9,562	68,912	61,484	621	7.207
2015	5,049	2,900	2,487	10,436	85,353	70,876	2,671	8.179
2016	5,198	3,484	2,404	11,086	90,296	74,051	3,709	8.145
2017	5,121	3,899	2,315	11,335	90,959	74,279	8,276	8.025
2018	5,550	4,330	2,488	12,368	98,742	81,333	10,954	7.984
2019	5,619	4,792	2,551	12,962	96,301	82,300	11,848	7.429
2020	3,587	3,484	1,840	8,911	66,078	55,957	8,067	7.415
2021	5,612	4,460	2,428	12,500	98,394	83,470	12,574	7.872
Total	53,023	36,347	20,285	109,655	849,650	724,096	58,720	7.701±0.443

N: number, OR: oocyte retrieval, FET: frozen embryo transfer, IUI: intrauterine insemination, RFID: radio-frequency identification, WP: witnessing point; average ± SD.

Table II: Overview of the total number of witnessing points, critical mismatches and critical administrator assigns per procedure

Procedure	N of WP	N of CMM	N of CAA
(i) sperm preparation	255,134	61	83
(ii) oocyte retrieval	69,585	3	34
(iii) IVF/ICSI	195,949	37	173
(iv) cleavage stage embryo and blastocyst biopsy	17,978	1	3
(v) embryo transfer	65,650	11	0
(vi) medium changeover	30,669	3	21
(vii) cryopreservation of oocytes and embryos	75,556	25	6
(viii) intrauterine insemination	40,513	3	0

N= number, WP: witnessing point, CMM: critical mismatch, CAA: critical administrator assign